Categories
Patents Pharma

[Archived Post] Policy Brief: The TRIPS Waiver for COVID-19 Vaccines, and Its Potential Expansion: Assessing the Impact on Global IP Protection and Public Health

This policy brief, including the following “Introduction and Executive Summary,” comes from Eric M. Solovy. CLICK HERE to read the brief in full. Introduction and Executive Summary On June 17, 2022, in the early morning hours of the final day of the World Trade Organization’s (“WTO”) 12th Ministerial Conference, the Members of the WTO adopted […]

Categories
Biotech C-IP2 News International Law Patents

[Archived Post] Panel Discussion: Vaccines, Intellectual Property, and Global Equity

The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2.  The COVID-19 pandemic has shined a spotlight on the role of intellectual property in modern medicine and on the complex social questions surrounding a system that grants exclusive rights over life-or-death products. On the one hand, there […]

Categories
Healthcare International Law

[Archived Post] A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines

Issue The United States and other wealthy nations have access to plenty of COVID-19 vaccine doses and thus are beginning to get the pandemic under control, while less affluent countries do not have access to adequate doses and are still struggling with rising cases. In October 2020, India and South Africa proposed addressing this problem […]

Categories
Healthcare Patents

[Archived Post] WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies

By Yogesh Pai Since October 2020, India and South Africa, joined by two-thirds of the WTO Members (African Group, LDCs and most of developing world) have been actively pursuing other developed country Members to agree to their request to waive global intellectual property (IP) rules. The waiver asserts that by suspending IP protection for COVID-19 […]

Categories
Antitrust Patent Law Pharma

[Archived Post] USPTO-DOJ Workshop on Promoting Innovation in the Life Science Sector: Day Two Recap

The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP.  By Austin Shaffer This past fall, the Department of Justice (DOJ) and U.S. Patent and Trademark Office (USPTO) hosted day two of their public workshop to discuss the importance of intellectual property rights and pro-competitive collaborations for […]

Categories
Copyright Innovation Patents Pharma

[Archived Post] IP Industries Step Up in This Time of Crisis

The global COVID-19 pandemic has challenged multiple aspects of modern society in a short time. Health and public safety, education, commerce, research, arts, and even basic government functions have had to change dramatically in the space of a couple months. Some good news in all this is the response of many companies in the intellectual […]